目的觀察普伐他?。╬ravastatin）對(duì)異種胰島移植物存活的影響。方法將豬→小鼠胰島移植模型分成A組（對(duì)照組）、B組（CsA組）、C組（普伐他汀組）、D組（CsA+普伐他汀組）。觀察指標(biāo)： 移植物存活時(shí)間、病理檢查、免疫組化染色、血清NO含量及移植物IFNγ mRNA的表達(dá)。結(jié)果A、B、C和D組移植物平均存活時(shí)間分別為（6.2±0.82） d、（9.2±1.92） d、（7.2±1.30） d及（11.2±1.76） d，D組存活時(shí)間明顯長(zhǎng)于其它3組（P＜0.05）； D組移植物浸潤(rùn)細(xì)胞較其它3組少。術(shù)后第4天，血清NO水平A組為（105.8±19.3） mmol/L，明顯高于B組的（88.2±21.4） mmol/L（P＜0.05）、C組的（70.7±17.8） mmol/L（P＜0.01）及D組的（56.3±16.4） mmol/L（P＜0.01），出現(xiàn)移植排斥時(shí)，C、D組的血清NO水平分別為（83.7±10.6） mmol/L及（71.3±13.8） mmol/L，仍較A組低（P＜0.05），B組為（104.7±16.3）mmol/L，與A組比較差異無(wú)顯著性意義（P gt;0.05）。術(shù)后第4天血清IFNγ mRNA表達(dá)，D組為23.5±4.6，較A組的28.8±4.8低（P＜0.05），而B、C組與A組間差異無(wú)顯著性意義（P gt;0.05）。結(jié)論普伐他汀能抑制巨噬細(xì)胞活性，延長(zhǎng)異種胰島移植物存活，尤其與CsA聯(lián)用效果更好。
引用本文： 魏正強(qiáng),.姚榛祥,黃平,董蒲江,楊光倫. 抑制巨噬細(xì)胞對(duì)異種胰島移植物的作用. 中國(guó)普外基礎(chǔ)與臨床雜志, 2003, 10(2): 121-124. doi: 復(fù)制
版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國(guó)普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編
| 1. | Nagata M, Mullen Y, Matsuo S, et al. Destruction of islet isografts by severe nonspecific inflammation [Ｊ]. Transplant Proc, 1990; 22(2)∶855. |
| 2. | Kaufman DB, Platt JL, Rabe FL, et al. Differential roles of Mac1+cells, and CD4+ and CD8+ T lymphocytes in primary nonfunction and classic rejection of islet allografts [Ｊ]. J Exp Med, 1990; 172(1)∶291. |
| 3. | Pukel C, Baquerizo H, Rabinovitch A. Destruction of rat islet cell monolayers by cytokines. Synergistic interactions of interferongamma, tumor necrosis factor, lymphotoxin, and interleukin 1 [Ｊ]. Diabetes, 1988; 37(1)∶133. |
| 4. | Kroncke KD, KolbBachofen V, Berschick B, et al. Activated macrophages kill pancreatic syngeneic islet cells via argininedependent nitric oxide generation [Ｊ]. Biochem Biophys Res Commun, 1991; 175(3)∶752. |
| 5. | Arita S, Une S, Ohtsuka S, et al. Prevention of primary islet isograft nonfunction in mice with pravastatin [Ｊ]. Transplantation, 1998; 65(11)∶1429. |
| 6. | Katznelson S, Wilkinson AH,Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantationa pilot study [Ｊ]. Transplantation, 1996; 61(10)∶1469. |
| 7. | Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation [Ｊ]. N Engl J Med, 1995; 333(10)∶621. |
- 1. Nagata M, Mullen Y, Matsuo S, et al. Destruction of islet isografts by severe nonspecific inflammation [Ｊ]. Transplant Proc, 1990; 22(2)∶855.
- 2. Kaufman DB, Platt JL, Rabe FL, et al. Differential roles of Mac1+cells, and CD4+ and CD8+ T lymphocytes in primary nonfunction and classic rejection of islet allografts [Ｊ]. J Exp Med, 1990; 172(1)∶291.
- 3. Pukel C, Baquerizo H, Rabinovitch A. Destruction of rat islet cell monolayers by cytokines. Synergistic interactions of interferongamma, tumor necrosis factor, lymphotoxin, and interleukin 1 [Ｊ]. Diabetes, 1988; 37(1)∶133.
- 4. Kroncke KD, KolbBachofen V, Berschick B, et al. Activated macrophages kill pancreatic syngeneic islet cells via argininedependent nitric oxide generation [Ｊ]. Biochem Biophys Res Commun, 1991; 175(3)∶752.
- 5. Arita S, Une S, Ohtsuka S, et al. Prevention of primary islet isograft nonfunction in mice with pravastatin [Ｊ]. Transplantation, 1998; 65(11)∶1429.
- 6. Katznelson S, Wilkinson AH,Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantationa pilot study [Ｊ]. Transplantation, 1996; 61(10)∶1469.
- 7. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation [Ｊ]. N Engl J Med, 1995; 333(10)∶621.